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A strong interest in the use of ceramics for biomedical engineering applications developed in the late 1960´s. Used initially 
as alternatives to metallic materials in order to increase the biocompatibility of implants, bioceramics have become a 
diverse class of biomaterials, presently including three basic types: relatively bioinert ceramics; bioactive or surface reactive 
bioceramics and bioresorbable ceramics. 
This review will only refer to bioceramics “sensus stricto”, it is to say, those ceramic materials constituted for nonmetallic 
inorganic compounds, crystallines and consolidated by thermal treatments of powders to high temperatures. Leaving 
bioglasses, glass-ceramics and biocements apart, since, although all of them are obtained by thermal treatments to high 
temperatures, the first are amorphous, the second are obtained by desvitrification of a glass and in them vitreous phase 
normally prevails on the crystalline phases and the third are consolidated by means of a hydraulic or chemical reaction to 
room temperature.
A review of the composition, physiochemical properties and biological behaviour of the principal types of crystalline 
bioceramics is given, based on the literature data and on the own experience of the authors. 
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phosphate
Materiales biocerámicos cristalinos
A finales de los años sesenta se despertó un gran interés por el uso de los materiales cerámicos para aplicaciones biomédicas. 
Inicialmente utilizados como una alternativa a los materiales metálicos, con el propósito de incrementar la biocompatibilidad 
de los implantes, las biocerámicas se han convertido en una clase diversa de biomateriales, incluyendo actualmente tres tipos: 
cerámicas cuasi inertes; cerámicas bioactivas o reactivas superficialmente y cerámicas reabsorbibles o biodegradables.
En la presente revisión se hace referencia a las biocerámicas en sentido estricto, es decir, a aquellos materiales constitutitos 
por compuestos inorgánicos no metálicos, cristalinos y consolidados mediante tratamientos térmicos a altas temperaturas. 
Dejando aparte los biovidrios, los vitrocerámicos y los biocementos, puesto que, si bien todos ellos son obtenidos por 
tratamiento térmicos a altas temperaturas, los primeros son amorfos, los segundos son obtenidos por desvitrificación de un 
vidrio, prevaleciendo normalmente la fase vítrea sobre las fases cristalinas, y los terceros son consolidados mediante una 
reacción química o hidráulica a temperatura ambiente.
Así pues, teniendo en cuenta la abundante bibliografía sobre el tema y la experiencia propia de los autores, se presenta una 
revisión de la composición, propiedades fisicoquímicas, aplicaciones y comportamiento biológico de los principales tipos de 
biocerámicas cristalinas.
Palabras clave: alúmina, zircona, alúmina-circona, grafito, hidroxiapatito, silicatos bioactivos, bioeutecticos, fosfato tricálcico.
1. INTRODUCTION
Bioceramics are those engineered materials that find their 
applications in the field of medicine [1]. Traditionally, the 
brittleness, the low mechanical fracture toughness and the 
low resistance to the impact have limited the applications 
of the ceramic materials. Nevertheless, a strong interest in 
the use of ceramics for biomedical engineering applications 
were developed at the end of the years sixty. New ceramics, 
with very improved properties, contributed to increase the 
possibilities of using ceramics in biomedicine and their use 
has extended considerably since then [2,3].
The great chemical inertia of the ceramics, their high 
compression strength and their aesthetic appearance, made 
that these materials began to be used in dentistry, mainly 
in dental crowns. Later their use extended to orthopaedic 
applications [4-6].
Used initially as alternatives to metallic materials in order 
to increase the biocompatibility of implants, bioceramics can 
be classified from different points of views [7, 8]:
(a) According to the type of answer of the living host
(b) According to the application to which they are destined 
[9]
(c) According to the characteristics of the material [10]
However, in this review, the classification, according to the 
answer of the living host, is going to be followed, because it 
is considered more in accordance with the application of the 
bioceramic materials. Then, according with this, bioceramics 
can be divided in Bioinert; Bioactive or Surface Reactive and 
Biodegradable or Resorbable Materials.
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2. BIOINERT CERAMICS
Relatively Bioinert ceramics undergo little or no chemical 
changes when they are exposed to physiological environments. 
They maintain their physical and mechanical properties while 
in the host. The answer of the host to these bioceramics is 
the formation of a very fine fibrous tissue capsule of varying 
thickness, several micrometers or less, that surround implant 
materials. The fixation of implants in the body is made through 
a strong mechanical interlocking, by tissue ingrowth into 
undulating surfaces [11]. When high strength is required, the 
bond is made by perforations in the implants using threads, 
cements, etc. When so high strength are not required can be 
used porous inert bioceramics, with sizes of pore between 100 
and 150 µm, which guarantee the growth of the tissue towards 
within implants assuring its fixation [12-14].
Typical examples of these bioinert ceramics are: Alumina 
(α-Al2O3); Zirconia (ZrO2), Alumina-Zirconia and Pyrolytic 
Carbon.
2.1. Alumina
Alumina of high density and purity (99.5 % in weight of 
α-Al2O3), with an average grain size < 4 µm is probably, the 
bioinert ceramic material of greater biological interest. This 
material was developed, as alternative to used metallic alloys 
in load-bearing hip prosthesis and in dental implants, to 
display an excellent biocompatibility, good resistance to the 
corrosion, to form a very fine fibrous capsule, to have a low 
coefficient of friction and good mechanical properties as much 
high strength as wear resistance [15-17].
According to the International Standards Organization 
(ISO), the purity of the alumina that is used in biomedical 
applications has to be over 99.5 %, being the rest of the 
impurities (SiO2, Na2O, K2O, CaO, etc.) below 0.1 % in weight, 
in order to avoid a large grain increase during sintering. 
An increase of average grain size to ∼7 µm can decrease 
mechanical properties by about 20 %. It is normal the addition 
of approximately 0.5 wt. % of MgO that acts as inhibitor of 
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prostheses. The first clinical use of total hip prosthesis with 
an alumina head and alumina socket was in 1971. The long-
term coefficient of the pair alumina/alumina and the wearing 
down index decrease with time and approaches the value of a 
normal healthy joint [18].
The main problem with total hip system is the loosening 
of the acetabular component, which is caused by wear debris. 
For this reason alumina is used only in the head of femur since 
numerous clinical studies indicates that alumina/ultrahigh 
molecular weigh polyethylene (UHMWPE) pair reduces wear 
Properties Al2O3 Implants ISO 6474-81
Al2O3 (wt. %) > 99,8 ≥ 99,50
Density (g/cm3) > 3,93 ≥ 3,90
Average grain size (µm) 3 – 6 < 7
Surface roughness (Ra) 
(µm) 0,02
Hardness (Vickers) 2300 > 2000
Compressive strength 
(MPa) 4500
Bending strength (MPa)* 550 400
Young modulus (GPa) 380
Toughness (KIc)(MPa m½) 5 - 6
Threshold (KI0) (MPa m½) ~ 2,5
TABLE I. CHARACTERISTICS OF AL2O3 IMPLANTS
the grain growth. Table I shows the characteristics of alumina 
implants, according to Ratner et al. [17], together with the ISO 
6474-81 requirements. 
The most common application of alumina bioceramics 
is in the area of orthopaedics as component in hip and knee 
debris by a factor of 10 or greater [19-21]. Figure 1 shows the 
typical microstructure of an alumina used in the femur head.
Other clinical applications of alumina are the used for 
screws, tooth-root implants, orbital walls, implants for 
maxillofacial reconstructions, dental implants etc. Between 
these last ones, the most well known application is the 
Tübingen implant [22-24] employee like substitute dental 
immediately after the extraction or in edentulous regions. The 
effectiveness of these implants is of 92.5 %. The cross-sectional 
fracture is the most frequent failure of these implants, due to 
relatively low resistance to the flexion, being the main cause 
of failure. Due to it, the use of alumina single crystals began 
to used as dental implant [25, 26] with resistance to flexion 3 
times over polycrystalline alumina. However, the use of single 
crystals do no eliminate the basic disadvantage of alumina 
bioceramics (low fracture toughness), which for alumina 
single crystals is equal to 4-5 MPa m1/2. These alumina single 
crystals are obtained generally by grown and crystallization 
from a melt or by the Verneuil method [27].
2.2. Zirconia
It has become a popular alternative to alumina as structural 
bioinert ceramics because, properly treated, it has a greater 
resistance to the fracture (greater fracture toughness) of any 
monolithic ceramics. On the other hand, zirconia is also 
exceptionally inert in the physiological environment and 
presents very good static fatigue strength. In addition, the 
zirconia/UHMWPE pair displays lower coefficient of friction 
than the alumina/UHMWPE pair, with the consequent 
diminution of particles to the physiological environment [28 
- 30].
Fig. 1.- Microstructure of an alumina for hip prosthesis obtained by 
HIP at 1500ºC.
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On the other hand, the potential radioactivity of the 
zirconia prosthesis, although the detected activity has been 
small, the long-term effects of the alpha radioactivity still must 
be evaluated. 
Nevertheless, very recently, French Government has 
prohibited the manufacture, distribution, export and use of 
these prostheses in France by decision of the July 22, 2003, 
because of having detected frequent breakage of femoral 
heads made in zirconia [37].
2.3. Alumina-Zirconia
Recently, the orthopaedic community reports significant 
in-vivo failures, due to the slow crack growth, of alumina and 
zirconia prostheses. Consequently, researches have been made 
with a new generation of alumina-zirconia nano-composites 
having a high resistance to crack propagation, which may offer 
the option to improve lifetime and reliability of ceramic joint 
prostheses. De Aza et al. [38, 39] have put in evidence that, 
tailoring the microstructure by refining powder processing 
using a new colloidal processing synthesis route, is possible 
to produce alumina-zirconia nano-composites at the top end 
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Zirconia presents three different crystalline forms: 
monoclinic, from room temperature to ∼ 1100 ºC, tetragonal, 
from this temperature to ∼2372 ºC, and cubic, from this last 
temperature to the melt at ∼2680 ºC. The monoclinic ↔ 
tetragonal transformation is of martensitic type, and therefore 
reversible when warming up or to cool down through the 
transition temperature (∼1100 ºC). This happens with an 
increase of volume of the order of 3 to 5 %, which produces 
the cracking or fracture of the pieces. In order to avoid this 
transformation, and even increase the toughness of the zirconia 
materials, the use of totally or partially stabilized tetragonal or 
cubic zirconia by suitable additives is recommended. Zirconia 
of higher toughness is usually obtained by stabilizing its 
tetragonal phase by doping it with yttria (∼3 mol %), followed 
by a suitable heat treatment, considering the binary system 
ZrO2 - Y2O3 [31]. In this way the zirconia bioceramic is totally 
a tetragonal material with a microstructure formed by very 
small grains of the order of 0.2 to 0.5 µm. The additives most 
widely used in biomedical applications are the yttria (Y2O3) 
and the magnesia (MgO).
Between all the ceramic materials, zirconia are those where 
their mechanical properties depend more of the sintering 
process, because is necessary to have a balance between the 
density and the average grain size of the bioceramic [32]. 
Figure 2 shows a typical microstructure of a tetragonal 
zirconia containing 3 mol % of yttria and Table II illustrates 
the characteristics of tetragonal zirconia stabilized with yttria 
(TZP = tetragonal zirconia polycrystals) versus partially 
stabilized zirconia with magnesia (Mg-PSZ = magnesia 
partially stabilized zirconia) [33].
Fig. 3.- Microstructure of an alumina - 10 vol.% zirconia nanocompos-
ite. Dark phase = alumina; clear phase = zirconia
Fig. 2.- Typical microstructure of a tetragonal zirconia containing 3 
mol % of yttria
Recently studies on new TZP materials, doped with yttria, 
tested in simulated body fluids and in animals, have shown 
slight decreases in fracture toughness and young modulus 
[34-36]. The observed strength, after two years, is sill much 
higher that the strength of alumina bioceramics tested under 
similar conditions. Because the zirconia/zirconia pair displays 
a wear rate 5000 times greater than the alumina/alumina pair, 
those do not have to be used in articulated surfaces.
TABLE II. CHARACTERISTICS OF TWO TYPES OF ZIRCONIA MATERIALS
Properties TZP Mg-PSZ
Purity ∼ 97 % ∼ 96.5
% Y2O3 3 mol %
% MgO 3,4 mol %
Density(g/cm3) 6.05 5.72
Average grain size (µm) 0.2 – 0.4 0.42
Bending strength (MPa) 1000 800
Compressive strength (MPa) 2000 1850
Young Modulus (GPa) 150 208
Hardness(Vickers) 1200 1120
Fracture toughness (KIC) (MPam½) 7 – 8 ∼ 8
Threshold (KI0) (MPam½) ~ 3,5 ± 0,2
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Its great cellular biocompatibility with the blood and the 
soft tissue as well as its excellent thromboresistance, does 
carbon material to be used fundamentally in applications 
of the circulatory apparatus, blood vessel and mechanical 
cardiac-valve prosthetic devices, being this last the most 
extended application. Nowadays, most of the modern heart 
valves are made with a coating of LTI on a polycrystalline 
graphite substrate or like a monolithic material [44].
In both cases is frequently added up to 10 wt.% of silicon, 
often in the form of discrete sub-micron β-SiC particles 
randomly dispersed in a matrix of roughly spherical micron-
size subgrains of pyrolitic carbon. The doping with silicon 
improves the mechanical properties of pyrolitic carbons, issue 
of great importance in the heart valves, where the joint is 
subject to degradation by cyclic fatigue or stress corrosion and 
possible cavitations by erosion during the life of the patient.
Some structural and mechanical properties of graphite and 
biomedical turbostratic carbons is shown in Table 4 [45].
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of they strength spectrum. Figure 3 shows a microstructure of 
one of these composite alumina-zirconia materials. These new 
composites can display not only a greater toughness (KIC) that 
the monolithic materials previously mentioned, otherwise, 
and what it is more important, a greater threshold for the 
stress intensity factor (KI0), under which crack propagation 
does not take place (Table III). This threshold represents an 
intrinsic property for a given material that gives information 
of its mechanical behaviour more realistic than the widely 
used toughness, which means only fast crack growth [40-41].
Material
Fracture 
threshold 
KI0(MPam½)
Tougnhess 
KIc(MPam½)
Hardness    H 
(Vickers)
Alumina (Al2O3) 2.5 ± 0.2 4.2 ± 0.2 1600±50
Zirconia
(3Y-TZP) 3.5 ± 0.2 5.5 ± 0.2 1290±50
Composite
(Al2O3-10% ZrO2)
4.0 ± 0.2 5.9 ± 0.2 1530±50
TABLE III. 
On the other hand, since hardness and chemical stability 
are equally important in the orthopaedic field, these composite 
materials, with relatively low contents of zirconia (10 % in 
volume), present similar hardness values than alumina (Table 
II) and are not susceptible to the hydrothermal instability 
observed in some cases of stabilised zirconia bioceramics (low 
temperature degradation). These nanomaterials may offer 
the option to improve the lifetime and reliability of ceramic 
femoral heads, so contributing to improve the quality of life 
of a large number of patients. Further, surgical operations and 
consequently the suffering of people as well as the high cost 
of such operations will be avoided.
2.4. Carbon
Carbon presents a great variety of forms: amorphous 
carbon, graphite, diamond, vitreous carbon and pyrolitic 
carbon. Some of them display the most excellent properties of 
biocompatibility, chemical inertia and thromboresistance that 
any other bioceramics. Another advantage of these materials 
is that their physical characteristics are close to those of the 
bone [42]. Thus, their densities, according to the type carbon, 
change between 1.5 - 2.2 g/cm3, and their elastic modules 
between 4 - 35 GPa. In spite of all the mentioned varieties, 
only three types of carbon are used for biomedical devices: 
the pyrolitic carbon, in its two varieties of low temperature 
isotropic (LTI) and ultra-low temperature isotropic (ULTI), 
and the vitreous carbon. The three types of carbon have 
disordered lattice structures and are collectively referred to as 
turbostratic carbons. While the microstructure of turbostratic 
carbon might seem very complicated due to its disordered 
nature, it is in fact quite closely analogous to the structure of 
graphite, but with at random oriented layers [43].
Pyrolitic carbon is widely used for implant fabrication. It 
is normally used as surface coating. Figure 4 shows a pyrolitic 
carbon deposited on a graphite fibre. Pyrolitic carbon devices 
are typically made, from a hydrocarbon gas in a fluidized-bed, 
via a chemical vapour-deposition method.
Properties
Polycrystalline 
Graphite
 Substrate
Silicon 
Alloyed LTI 
Pyrolitic 
Carbon
ULTI Vapor 
Deposited 
Carbon
Density (kg. m-3) 1,500 – 1,800 1,700 – 2,200 1,500 – 2,200
Crystalline Size (nm) 15 – 250 3 – 5 8 - 15
Expansion Coefficient 
(10-6 K-1) 0,5 – 5 5 – 6 ---
Hardness (DPH) 50 – 120 230 – 370 150 – 250
young´s modulus 
(GPa) 4 – 12 27 – 31 14 – 21
Flexural Strength (mPa) 65 – 300 350 – 530 345 - 690
Fracture Strain (%) 0.1 – 0.7 1.5 – 2.0 2.0 – 5.0
Fracture Toughness 
(mPa m½) ∼1.5 0.9 – 1.1 ---
 
TABLE IV. STRUCTURAL AND MECHANICAL PROPERTIES OF GRAPHITE AND 
BIOMEDICAL TURBOSTRATIC.
Fig. 4.- Pyrolitic graphite (PG) deposited on a graphite fiber (GF)[45]
Whereas the pyrolitic carbons coating have been applied 
in zones in contact with the blood, due to their excellent 
thromboresistance, the vitreous carbons have been studied 
mainly to bond to soft and hard tissues, without inflammatory 
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proposes in 1967 to the U.S.A. Army Medical Research and 
Development Command, a research based on the modification 
of the chemical composition of ceramics, and glasses so that 
they have chemical reactivity with the physiological system 
and form chemical bond between the surfaces of implant 
materials and the adjacent tissue. 
Upon implantation in the host, bioactive ceramics form a 
strong bond with adjacent tissue. Except hydroxyapatite, which 
bond directly to living bone, the rest of bioactive materials 
bond to bone through a carbohydroxyapatite layer (CHA) 
biologically active, which provides the interfacial union with 
the host. This phase is chemical and structurally equivalent 
to the mineral phase of the bone, and the responsible of the 
interfacial union. 
The interface of union between bioactive materials and 
tissue is usually extremely strong. In many cases, the interfacial 
strength of adhesion is equivalent to or greater than the 
cohesive strength of the implant material or the tissue bonded 
to the bioactive implant. Generally, the break takes place in 
the implant or in the bone but almost never in the interface 
[60-63].
However, not only certain types of glasses and glass-
ceramics are bioactives. Other ceramic materials “sensus 
stricto” are also bioactives. The typical example is the 
hydroxyapatite, which is the only one that bond directly 
to bone and other examples are: certain silicates (diopside 
and wollastonite) and a new group of ceramic materials 
denominated Bioeutéctics, as it will be exposed next.
3.1. Hydroxyapatite
Hydroxyapatite (HA) is the primary mineral content of 
bone representing ∼43 wt.%. HA is a calcium phosphate whose 
stoichiometric formula corresponds to a: Ca10(PO4)6(OH)2, with 
a Ca/P molar ratio = 1.67. HA belong the mineral family of 
Apatites whose name derived from Greek “απαταω” means 
deception or deceit, due to the facility it was confused with 
other mineral species like the beryl or the tourmaline [64].
HA displays ionic character, and its crystalline structure 
can be describe like a compact hexagonal packing of oxygen 
atom with metals occupying the tetrahedral and octahedral 
holes of the periodic network. The basic apatite structure 
is hexagonal with space group P63/m and approximate 
lattice parameters a=9.4 and c=6.9 Å, being the fluorapatite 
(Ca10(PO4)6F2) the representative example of this structure. 
Nevertheless, HA presents a low symmetry, monoclinic, 
due to the distortion of the ion OH¯ with respect to the ideal 
model that would represent the position of spherical ion F¯ 
in the fluorapatite. Nevertheless, in most of the works in the 
field of biomaterials it assumed that HA has a fluorapatite 
structure but with lattice parameter a=b=9,418 Å and c=6,884 
Å. α=ß=90° and γ=120°, Z=2. The unit cell contains 10 Ca+2, 6 
PO43- and 2 groups OH¯ [65].
HA allows the substitution of many other ions in their 
structure. These substitutions can take place in the positions 
of the calcium ions (Ca2+) or in the phosphate groups (PO4)3 or 
hydroxyls groups (OH)−. Consequences of these substitutions 
are changes in its properties like lattice parameters, 
morphology, solubility etc., without significant change in the 
symmetry. Thus for example, the substitution of F− by OH− 
involve a contraction in the a axis without change in the c 
axis, associated to an increase in the crystallinity and imparts 
greater stability to the structure. On the other hand, this imply 
that the fluorapatite is less soluble than the HA and that all 
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answer in the adjacent tissues. Similar behaviour has been 
registered for pyrolitic carbons LTI and ULTI. 
Apart from of the mistral and aortic heart valves, there are 
applications in dental field [46] and middle ear reconstruction 
and in devices of LTI coating on titanium to make easy the 
circulation of the blood. Recently, success was achieved in 
coating ULTI onto the surfaces of blood vessel implants made 
of polymers. The coating has excellent compatibility with 
blood and is thin enough not to interfere with the flexibility 
of the grafts [47].
3. BIOACTIVE CERAMICS
Generally, when an artificial material is implanted in 
the body, it is encapsulated by uncalcified fibrous tissue 
that isolates it from the surrounding. This is a normal 
reaction intended to protect the body from foreign substances. 
However, in the early 1970s, Hench et al. [48] found that a 
glass, called Bioglass®; of the complex system Na2O-CaO-
SiO2-P2O5, induced the formation of no fibrous tissue, but 
rather came into direct contact with the surrounding bone and 
formed a tight chemical bond with it.
Since then, other types of glasses and glass-ceramics have 
also been found to bind to living bone [49-51], Hench et al.[52-
53], Gross et al. [54-55], Karlon et al. [56-57] and Kokubo et 
al. [58-59]. These bone-binding materials are called bioactives 
materials. 
The appearance of this type of bioceramics born of the need 
to eliminate the interfacial movement that takes place with the 
implantation of bioinert ceramics. Consequently, L. L. Hench 
Fig. 5.- (a) TEM image showing overall morphology of the HA crystals. 
(b) High-resolution TEM image of HA crystals and (c) Selected-area 
diffraction pattern of the region. HA acicular crystals change to rods to 
equi-axed crystals with increasing carbonate content
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seems to indicate that bioactive materials can be obtained 
with compositions based on the CaO-SiO2 system rather than 
in the CaO-P2O5. Taking into account these observations, 
Noami et al. [79, 80] and De Aza et al. [81-92] have shown 
that two polycrystalline chain silicate materials: diopside and 
wollastonite are also bioactives.
3.2.1. Wollastonite
Pseudowollastonita (CaSiO3), the high temperature form of 
wollastonite, displays in its structure calcium ion chains easily 
removals by protons, as Bailey and Reesman [93] showed it 
in the study of the kinetic of dissolution of the wollastonite 
in H2O-CO2 systems. This fact suggests the possibility of 
extraction of calcium ions, from the wollastonite structure, by 
protons from the SBF, facilitating therefore the precipitation 
and formation of a HA layer on the surface of the material.
De Aza et al. have demonstrated the formation of a HA-
like layer on the surface of pseudowollastonite ceramic both 
in vitro” [81-83, 85, 90] and “in vivo” [86,87]. Experiments 
“in vitro” involved immersion of the material in SBF with an 
ion concentration, pH and temperature virtually identical to 
human blood plasma, and in human parotid saliva (HPS).
Figure 6 shows the overall microstructure of a polished 
cross-section of the pseudowollastonite sample after one-
month immersion in simulated body fluid and its relevant 
X-ray maps for calcium, silicon and phosphorous elements. 
This microcharacterisation of the interface showed that the 
reaction zone was composed of two chemically dissimilar 
layers formed on the pseudowollastonite surface. The outer 
layer was composed of a CaO/P2O5-rich phase, identified as 
HA-like phase by thin-film X-ray diffraction [83], while the 
underlayer, in direct contact with the pseudowollastonite 
substrate, was rich in amorphous silicon as was characterized 
by TEM, selected-area diffraction pattern and EDS analysis 
[83].
F¯ free apatites, including biological apatites. Many other 
ions can enter in the HA network, affecting the properties, 
crystallinity, thermal stability, rate of dissolution etc.
The mechanical properties of the HA are similar to those of 
the most resistant components of the bone. HA has an elastic 
modulus of 40-100 GPa; dental enamel: 74 GPa, the dentine: 
21 GPa, and the compact bone: 18-12 GPa. Nevertheless, 
dense bulk compacts of HA have mechanical resistances of 
the order of 100 MPa versus the 300 MPa of the human bone, 
diminishing drastically their resistances in the case of porous 
bulk compacts..
HA differs from biological apatites (enamel, dentin, bone, 
etc.) in physical and mechanical properties, stoichiometry, 
composition, crystallinity and other properties. Biological 
apatites are usually calcium-deficient and are always carbonate 
substituted. It is therefore more appropriate that biological 
apatites be referred as carbonate apatite (carbohydroxyapatites) 
a not as hydroxyapatite or HA, where groups (CO3)2- replace 
group (PO4)3- and where the Ca2+ is replaced by Na+ to balance 
the charges [66, 67].
The methods of obtaining HA are very varied, including 
hydrothermal systems, precipitation methods, hydrolysis, 
solid-state reactions and hydrothermal reactions (68–70). 
However, when prepared from aqueous reactions either 
by precipitation or hydrolysis methods, the HA obtained is 
usually calcium deficient (Ca/P molar ratio lower than the 
stoichiometric value of 1.69). When the precipitation reaction 
is carried out under very basic conditions, the precipitate will 
contain carbonate, which makes the Ca/P molar ratio higher 
than the stoichiometry value. Figure 5 shows an electron 
image of CO3-apatite crystals.
The interest as biomaterial of HA comes clearly by its 
similarity with the mineral phase of the bone tissue. In 
principle, HA would be the most suitable material as much for 
the restoration as for the substitution of the bone. However, 
the relatively low strength and toughness of HA arouses little 
interest among researchers when the focus of attention is on 
dense structural samples. Therefore, its use is restricted to all 
those applications where mechanical efforts are not required, 
finding its application mainly as coating on metallic substrata, 
with the object to accelerate and to increase the fixation of 
prostheses to the bone [71, 72]. 
Industrial and laboratory techniques, used for HA 
coating onto metallic substrates, include plasma spraying, 
laser ablation, electrophoretic deposition, sputtering and 
hot isostatic pressing. Being the first one, the most used, 
mainly in the coating of hip prostheses, being achieved, 
in this way, what has been called biological fixation of the 
prosthesis. [73, 74]. Among other applications are: a) coating 
of dental and maxillofacial prosthesis; b) dental implants; c) 
middle ear reconstruction; d) augmentation of alveolar ridge; 
e) periodontal defects; f) spinal surgery; g) pulp-capping 
materials [75].
3.2. Bioactive Silicates
It has been considered that to show bioactivity, glasses and 
glass-ceramics must contain both CaO and P2O5, which are the 
main components of the hydroxyapatite [76, 77]. Conversely, 
Ohura et al. [78] have recently observed that CaO-SiO2 glasses, 
free of P2O5 as well as those containing very small amounts of 
P2O5, form the HA layer on their surfaces (bioactivity), when 
they are soaked in simulate body fluid (SBF), whereas CaO-
P2O5 glasses free of SiO2 do not form HA layer in SBF. This 
Fig. 6.- SEM image of a cross-section of pseudowollastonite after one 
month immersion in SBF and X-ray elemental maps of Ca, Si and P
The mechanism involved in the HA layer formation was 
described by De Aza et al.[94] as follows: at pH 7.25 of the 
SBF, the reaction mechanism start through an ionic exchange 
of H3O+, from the SBF, by labile calcium ions. This induces 
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the formation of an amorphous hydrogel silica layer and a 
sudden increase in pH from 9.0 to 10.5 at the wollastonite/SBF 
interface. This condition determines the partial dissolution 
of amorphous silica and the subsequent precipitation of HA. 
According to De Aza et al., this mechanism is common for both 
amorphous and crystalline silica-based bioactive material. 
The authors also have evaluated the cytotoxicity of the 
pseudowollastonita [89] and the suitability of the material 
as a substratum for cell attachment and the ability to affect 
osteoblast at a distance from the material surface [91, 92]. These 
experiments demonstrate that extracts of pseudowollastonite 
do not show any significant cytotoxic effects and confirm 
the biocompatibility of this material. On the other hand, 
osteoblastic cells attached and proliferated on the surface 
to the ceramic. In addition, osteoblastic cells, at a distance 
form the material, exhibited a dramatic alteration on their 
appearance. This reinforces the suggestion that the release 
of soluble factors, silicon and calcium from the wollastonite, 
is responsible for much of the biological activity of this 
material. 
“In vivo” experiments were consisted of implanting 
small cylinders of pseudowollastonite into rat tibias [86, 
87]. Histological observations twelve weeks after implant 
show that the bone in contact with the surface of the 
pseudowollastonite appeared to be progressively replaced by 
bone with laminar arrangement. The new bone was growing 
in direct contact with the pseudowollastonite implants after 
only 3 weeks. Figure 7 shows SEM micrograph of polished 
cross-sections of pseudowollastonite implant after six weeks 
of implantation. The individual X-ray maps of the silicon, 
calcium and phosphorous distribution are also included. The 
calcium phosphate phase corresponds to new bone tissue 
as reported by histological examination. At twelve weeks of 
implantation, new bone was still growing at the interface.
Overall, these results suggest that pseudowollastonite 
is biocompatible and osteoconductive and it can be used 
for substitution or repair of bone tissues in places where 
mechanical solicitations are not high.
3.3. Wollastonite-Tricalcium Phosphate (Bioeutectic)
Natural and synthetic materials have been used clinically 
for many years to reconfigure anatomic structures for aesthetic 
and therapeutic reasons in several different surgical situations, 
however many outstanding problems remain unsolved. 
The most important is the process of total osteointegration 
of ceramic implants in the human body. When bioactive 
materials are implanted in a living body, the interaction 
between the bone tissue and these materials usually take place 
only on their surfaces, with the remaining bulk of the material 
unchanged, often causing a harmful shear stress. 
To improve the ingrowth of new bone into implants 
(osteointegration), the use of materials with an appropriate 
interconnected porous structure has been recommended [95-
100]. The design of a porous ceramic implant material has the 
potential of controlling the bone ingrowths. However, porous 
materials have very poor mechanical properties.
A new approach to overcoming this problem was proposed 
by De Aza et al [101-106].This is based on designing dense 
bioactive ceramic materials with the ability to develop an in 
situ porous hydroxyapatite-like (HA) structure when they are 
implanted into a living body. The material was composed of 
Fig. 7.- SEM image of a cross-section of pseudowollastonite implant af-
ter six weeks of implantation and X-ray elemental map of Si, Ca and P
Fig. 8.- SEM image of the microstructure of the eutectic material 
(Bioeutectic) and detail of a colony. White and black lamellae pseu-
dowollastonite and -tricalcium phosphate respectively. Sample etch-
ing with dilute citric acid. 
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two phases, pseudowollastonite (CaSiO3 = psW) of bioactive 
character and resorbable α-tricalcium phosphate (α-TCP). 
Taking into account the bone structure, the microstructure 
of the material was developed by slow solidification of the 
eutectic composition of the system wollastonite-tricalcium 
phosphate (60 wt% psW and 40 wt% α-TCP)[107].
Figure 8 shows a SEM image of the microstructure of 
the eutectic material (Bioeutectic), which consists of quasi-
spherical colonies formed by alternating lamellae of psW 
and α-TCP with a morphology which correspond to irregular 
eutectic structure [108-110].
The material, exposed to simulated body fluid (SBF) for one 
week, transforms partially dissolving the pseudowollastonite 
lamellae and forming a porous structure of HA-like that 
mimic porous bone by a pseudomorphic transformation of the 
α-TCP, according to the reaction: 
3[Ca3(PO4)2] + Ca2+ + 2(OH)- → Ca10(PO4)6(OH)2
Figure 9 shows clearly the partial dissolution and 
transformation of the Bioeutectic after one week soaking in 
SBF.
ideals implants, since only remain in the body while their 
function is necessary and disappear as the tissue regenerates. 
Their greater disadvantage is that their mechanical strength 
diminishes during the reabsorption process. 
Consequently, the function of these materials is to participate 
in the dynamic process of formation and reabsorption that 
takes place in bone tissues; so they are used like scaffolding 
or filling spaces allowing to the tissues their infiltration and 
substitution [111].
All the resorbable ceramics, except plaster (CaSO4½H2O), are 
based on calcium phosphates, varying their biodegradability 
in the sense:
α-TCP > β TCP >>>> HA
The biodegradation rate is increased, as it is logical, 
as: a) specific surface increases (powders are more quickly 
biodegraded that porous solids and these more quickly 
than dense solids); b) when crystallinity decreases; c) when 
grain and crystal size decrease; d) when e.g. there are ionic 
substitutions of CO32-, Mg2+ and Sr2+ in HA. 
The factors that tend to decrease the rate of biodegradation 
include e.g.: a) F¯ substitution F¯ in HA; b) Mg2+ substitution 
in β- TCP and c) lower β- TCP/HA ratios in biphasic 
compounds. 
Fig. 9.- SEM image of a cross-section of the Bioeutectic after one week 
soaking in SBF and Si, P, and Ca X-ray maps.
Conversely, when the material is immersed in a slow 
stream of SFB (50 cm3/h) instead of using a static solution, 
them a complete transformation of the material takes place 
given rise to a HA artificial porous bone as is shown in Figure 
10.
Therefore, the Bioeutectic material is the only bioactive 
material, at present, which is totally colonized in SBF. 
Consequently, it is expected it behaves similarly in in vivo 
experiments facilitating the osteointegration of the implant. 
These studies are actually carried out.
4. BIODEGRADABLE OR RESORBABLE MATERIALS
The resorbable ceramics began to be used in 1969. These 
types of bioceramics are dissolved with time and are gradually 
replaced by natural tissues. A very thin or non-existent 
interfacial thickness is the final results. They would be the 
Fig. 10.- SEM images of a fresh fracture of the Bioeutectic after im-
mersion in a stream of SBF for three weeks. (A) General view of the 
material completely transformed into a porous HA structure similar to 
porous bone. (B) Detail of a colony after transformation.
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The biodegradation or reabsorption of calcium phosphates 
is caused by three factors:
1) Physiochemical dissolution, which depends on 
the solubility product of the material and local pH of its 
environment. New phases may be formed, such as amorphous 
calcium phosphates, dicalcium phosphate dihydrate, 
octacalcium phosphate, and anionic substituted HA.
2) Preferential attack of the grain boundaries and physical 
disintegration in small particles.
3) Biological factors, such as phagocytosis, which causes 
a decrease in local pH concentration, the cellular activity and 
the site of implantation.
One of the few bioceramics that satisfy partially these 
requirements is the tricalcium phosphate (TCP).
4.1. Tricalcium phosphate
The tricalcium phosphate (TCP) is the biodegradable 
phosphate par excellence. TCP has a stoichiometric formula 
Ca3(PO4)2 with a Ca/P molar ratio = 1.15. The TCP is a neutral 
compound in which the 6 positive charges of the Ca+2 ions 
are compensated by 6 negative charges of the anions PO43¯. 
It belongs to the family of the Whitlockites that respond to 
general formulate (Ca,Mg)3 (PO4)2, so that the calcium can be 
replaced partial or totally by magnesium.
The TCP is a material that displays polymorphism. Three 
polymorphs are known: β, α and α` phases, from low to high 
temperature of stability respectively [112,113]. 
The β phase crystallizes in the hexagonal system, and 
their lattice parameters are: a = 10.429Å and c = 37.38Å. α=β= 
90° and γ=120°. The α phase crystallizes in the orthorhombic 
system with lattice parameters: a = 15,22 Å, b = 20,71 Å and c 
= 9.109Å. α=β= γ= 90° and finally the α´phase crystallize in the 
monoclinic system, with lattice parameters: a = 12.887Å, b = 
27.280Å and c = 15.219Åα=γ= 90° and β=126.2° [114].
The β phase is stable from room temperature up to 1150 ± 
10 ºC ºC to which transforms into the α phase. This is stable 
from this temperature up to 1475 ± 5 ºC to which transforms 
into the α´ phase which is stable up to the melting temperature. 
The α ↔- α´ transition is completely reversible in both senses. 
Equally it happens with the α ↔ β transition, although if the 
α phase is abruptly quenched it can be mestastably preserved 
at room temperature.
As the synthesis of HA, the synthesis of β-TCP, in aqueous 
solution, is affected by many physical and chemical parameters, 
what presents great difficulty to obtain a product 100% pure 
[115-116]. However, pure β-TCP can be easily obtained by 
solid state reaction of calcium and phosphorus compounds 
with relationships Ca/P = 1,5.
Applications are temporary fillings and periodontal 
defects.
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